Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients

Autor:	Sohail Ikram, Kathy D. Miller, Adrian P. Gee, Joshua M. Hare, Jay H. Traverse, Bharath Ambale-Venkatesh, Emerson C. Perin, Connor O'Brien, Judy Bettencourt, Ray F. Ebert, Timothy D. Henry, Roberto Bolli, Joao A.C. Lima, Carl J. Pepine, Dejian Lai, David P. Lee, Phillip C. Yang, Shelly L. Sayre, Keith L. March, Michelle Cohen, Lara M. Simpson, Sara Richman, Michael P. Murphy, Doris A. Taylor, Mohammad R. Ostovaneh, Lem Moyé, Raul D. Mitrani, Rachel W. Vojvodic, Robert D. Simari, Catalin Loghin, Jean-Bernard Durand, James T. Willerson, David Aguilar, Barry R. Davis
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Chemotherapy Poor prognosis Anthracycline business.industry medicine.medical_treatment Mesenchymal stem cell Cardiomyopathy medicine.disease Internal medicine Heart failure medicine Stem cell Young adult Cardiology and Cardiovascular Medicine business
Zdroj:	JACC: CardioOncology. 2:581-595
ISSN:	2666-0873
DOI:	10.1016/j.jaccao.2020.09.001
Popis:	Background Anthracycline-induced cardiomyopathy (AIC) may be irreversible with a poor prognosis, disproportionately affecting women and young adults. Administration of allogeneic bone marr...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9ee32c847cdd002c48ab2a56bb8e82a1 https://doi.org/10.1016/j.jaccao.2020.09.001 Zobrazit plný text záznamu